Henoch-Schönlein purpura (HSP), also known as anaphylactoid purpura is a clinically recognizable systemic disorder occurring in children, mainly from ages 3 to 10 years.
To describe the clinical, epidemiological, and laboratory findings in a group of patients with recurrent HSP, admitted to a tertiary pediatric center.
Retrospective analysis of medical records of patients hospitalized due to HSP between 1969 and 2004.
Two hundred sixty children (56.7% males) were hospitalized due to HSP, 7 (2.7%) more than once. There were no statistically significant differences in demographic or clinical characteristics between the patients with 1 event of HSP and patients with recurrence. Mean age of the subgroup with recurrence was 3.67 years (10 months to 7.4 years) at the first episode, and 5.03 years (2.2–10 years) at the second one, with a mean lag period of 13.5 ± 2.8 months (range 2–26). The duration of the recurrent clinical symptoms ranged from 9 to 30 days, and in 72% of those patients, resolution took more than 14 days.
In our inpatient population, no clinical or laboratory characteristics were found to be predictive of recurrence; the second episode was longer than the first and the lag period between the 2 episodes was substantially longer than previously reported. Hospital admissions for recurrent HSP are not common. Nevertheless, a good prognosis was the rule of our admitted patients.
2.7% of children admitted with Henoch-Schönlein purpura had recurrences requiring readmission after 2–26 months. There are no significant predictors of these exacerbations, and outcomes were still excellent.
From the Department of Pediatrics C, Schneider Children's Medical Center of Israel, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Reprints: D. Prais, MD, Department of Pediatrics C, Schneider Children's Medical Center of Israel, 49202 Petah Tiqva, Israel. E-mail: email@example.com